Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Neoplasms Breast Diseases Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Pfizer Investigational Site, Bordeaux, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Post-menopausal patients with unilateral breast cancer T2 to T4, N0-1, M0, non inflammatory, operable, hormonal receptors positive

Exclusion criteria

Patients with bilateral breast cancer T4d, inflammatory, non operable, hormonal receptors negative

Treatment and study plan

exemestane (Aromasin®)

Drug

Primary outcomes

To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)

Secondary outcomes

To evaluate breast conservative surgery rate; To evaluate intratumoral anti-aromatase activity.

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

Phase II Study Evaluating The Role Of Exemestane On Clinical And Pathologic Response Rates, And Its Aromatase Activity As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients.

Important dates

Study start: 2001
Study completion: 2006
First posted: Sep 15, 2005
Registry last updated: Apr 22, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed